GlobeStar Therapeutics Corporation (GSTC)
GlobeStar Therapeutics Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $124,111. On trailing twelve-month figures it carries a trailing P/E of -0.04, a net margin of 0.0%. Its beta of 1.11 implies it has historically moved more than the broad market.
GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing proprietary drug formulations. These innovative treatments specifically target multiple sclerosis (MS) and various other neurodegenerative disorders. Established in 2016, the company was formerly known as AngioSoma, Inc., rebranding to GlobeStar Therapeutics Corporation in July 2021. Its operations are headquartered in Richland, Washington.
GlobeStar Therapeutics Corporation is most often compared with the following Healthcare names: